Barclays analyst Hassan Al-Wakeel upgraded Fresenius Medical Care to Overweight from Equal Weight and raised his price target for the shares to 81.50 euros from 71 euros. After speaking with CEO Rice Powell and a deep-dive into U.S. dialysis market fundamentals, the analyst believes market concerns around the medium-term sustainability of growth are likely overdone. The analyst has started to see some improvements in the business and believes expectations are now achievable. He now sees a "compelling" risk/reward over the medium term for shares of Fresenius Medical.